Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 307-313

  Dusenbery, Kathryn E ^a   Bellairs, Ellen E ^a   Potish, Roger A ^a   Twiggs, Leo B ^a   Boente, Matthew P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Abdominal radiotherapy; Consolidation therapy; Long term follow up; Melphalan; Ovarian cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; VINCRISTINE;

ABDOMINAL RADIOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MYELOID LEUKEMIA; OVARY CARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 12344328271     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.08.040     Document Type: Article

References (45)

1. A. Jamal, T. Murray, and A. Samuels Cancer statistics, 2004 CA Cancer J. Clin. 53 2004 8 29
2. P.J. DiSaia, and W.T. Creasman Epithelial ovarian cancer Clinical gynecologic oncology sixth ed. 2002 Mosby St. Louis 289 350
3. B.L. Hintz, Z. Fuks, and R.L. Kempson Results of postoperative megavoltage radiotherapy of malignant surface epithelial surface tumors of the ovary Radiology 114 1975 695 700
4. J.P. Smith, F.N. Rutledge, and L. Delclos Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy Natl. Cancer Inst. Monogr. 42 1975 149 153
5. D.B. Fuller, W.T. Sause, and H.P. Plenk Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma J. Clin. Oncol. 5 1987 897 905
6. A. Martinez, M.F. Schray, and A.E. Howes Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience J. Clin. Oncol. 3 1985 901 911
7. A.J. Dembo Abdominopelvic radiotherapy in ovarian cancer: a 10-year experience Cancer 55 1985 2285 2290
8. R.A. Potish, L.B. Twiggs, and L.L. Adcock Logistic models for prediction of enteric morbidity in the treatment of ovarian and cervical cancers Am. J. Obstet. Gynecol. 147 1983 65 72
9. R. Potish, L. Adcock, and D. Brooker Sequential surgery, radiation therapy, and Alkeran in the management of epithelial carcinoma of the ovary Cancer 45 1980 2754 2758
10. Anon Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecologists and Oncologists Am. J. Obstet. Gynecol. 156 1987 263 264
11. S. Serov, and R. Scully Histologic typing of ovarian tumors Int. Histol. Classif. Tumours vol. 9 1973 World Health Organization Geneva
12. A. Borders Carcinoma: grading and practical application Arch. Pathol. 2 1926 376 381
13. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observation Am. Stat. Assoc. J. 53 1958 457 481
14. N. Mantel Evaluation of survival data and two new rank-order statistics arising in its consideration Cancer Chemother. Rep. 50 1966 163 170
15. O.H. Beahrs, D.E. Henson, and V.P. Hutter Reporting of cancer survival and end results Manual for staging of cancer third ed. 1988 JB Lippincott Co. Philadelphia 11 24
16. Anon. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. 2003. (http://ctep.cancer. gov).
17. T. Thigpen, R. Vance, and L. Puneky Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials Gynecol. Oncol. 55 1994 S97 S107
18. R.R. Reimer, R. Hoover, and J.J. Fraumeni Jr. Acute leukemia after alkylating-agent therapy of ovarian cancer N. Engl. J. Med. 297 1977 177 181
19. S. Firat, K. Murray, and B. Erickson High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes Int. J. Radiat. Oncol. Biol. Phys. 57 2003 201 207
20. H. Pickel, M. Lahousen, and E. Petru Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer Gynecol. Oncol. 72 1999 215 219
21. B. Sorbe Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment Int. J. Gynecol. Cancer 13 2003 278 286
22. H.E. Lambert, G.J. Rustin, and W.M. Gregory A randomized clinical trial comparing single-agent carboplatinum followed by radiotherapy for advanced ovarian cancer. North Thames Ovary Group Study J. Clin. Oncol. 11 1993 440 448
23. F. Lawton, D. Luesley, and B.G. Blackledge A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II Clin. Oncol. 2 1990 4 9
24. M. Bruzzone, L. Repetto, and S. Chiara Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look Gynecol. Oncol. 38 1990 392 395
25. H. Goldberg, M.E. Stein, and M. Steiner Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up Tumori 87 2001 248 251
26. G.M. Thomas, and A.J. Dembo Integrating radiation therapy into the management of ovarian cancer Cancer 71 1993 1710 1718
27. R.R. Reimer, R. Hoover, and JJ. Fraumeni Jr. Second primary neoplasms following ovarian cancer J. Natl. Cancer Inst. 61 1978 1195 1197
28. S.F. Dent, D. Klaassen, and J.L. Pater Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) Ann. Oncol. 11 2000 65 68
29. S. Kehoe, and J.E. Powell Prior, synchronous, and secondary malignancies in women with ovarian cancer Int. J. Gynecol. Obstet. 73 2001 265 267
30. H.I. Hall, P. Jamison, and HK. Weir Second primary ovarian cancer among women previously diagnosed with cancer Cancer Epidemiol. Biomarkers Prev. 10 2001 995 999
31. J.E. Nevin III, G. Pinzon, and T.J. Baggerly The use of intravenous phenylalanine mustard followed by supervoltage irradiation in the treatment of carcinoma of the ovary Cancer 51 1983 1273 1283
32. A.W. Fyles, G.M. Thomas, and M. Pintilie A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked stage I, II, and III ovarian cancer Int. J. Radiat. Oncol. Biol. Phys. 41 1998 543 549
33. L. Hong, K. Alektiar, and C. Chui IMRT of large fields: whole-abdomen irradiation Int. J. Radiat. Oncol. Biol. Phys. 54 2002 278 289
34. W. Duthoy, W. De Gersem, and K. Vergoete Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience Int. J. Radiat. Oncol. Biol. Phys. 57 2003 1019 1032
35. N.R. Ahmad, M.S. Huq, and B.W. Corn Respiration-induced motion of the kidneys in whole abdominal radiotherapy: implications for treatment planning and late toxicity Radiother. Oncol. 42 1997 87 90
36. M. Rosu, L.A. Dawson, and J.M. Balter Alterations in normal liver doses due to organ motion Int. J. Radiat. Oncol. Biol. Phys. 57 2003 1472 1479
37. A.E. Lujan, A.J. Mundt, and S.D. Yamada Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 57 2003 516 521
38. M. Adli, N.A. Mayr, and H.S. Kaiser Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer? Int. J. Radiat. Oncol. Biol. Phys. 57 2003 230 238
39. T.J. Whelan, A.J. Dembo, and R.S. Bush Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer Int. J. Radiat. Oncol. Biol. Phys. 22 1992 853 858
40. N.P. Nguyen, J.E. Antoine, and S. Dutta Current concepts in radiation enteritis and implications for future clinical trials Cancer 95 2002 1151 1163
41. M.C. Vozenin-Brotons, F. Milliat, and C. Linard Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization Radiat. Res. 161 2004 299 311
42. A. Francois, and F. Milliat 'In-field' and 'out-of-field' functional impairment during subacute and chronic phases of experimental radiation enteropathy in the rat Int. J. Radiat. Biol. 79 2003 437 449
43. S. Davis-Perry, E. Hernandez, and K.L. Houck Melphalan for the treatment of patients with recurrent epithelial ovarian cancer Am. J. Clin. Oncol. 26 2003 429 433
44. J. Hasan, and G.C. Jayson Oral melphalan as a treatment for platinum-resistant ovarian cancer Br. J. Cancer 88 2003 1828 1830
45. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carbolplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 21 2003 194 200